Home > Insider Trading > Filing (0001225208-17-002833)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
9892	Bard C R Inc	BCR	Surgical & Medical Instruments & Apparatus (3841)	221454160

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1271440	S Christopher Holland	C/O C. R. Bard, Inc. 730 Central Avenue Murray Hill NJ 07974	Senior Vice President And Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-02-08	11,746	$0.00	35,751	No	4	A	Direct
Common Stock	Acquisiton	2017-02-08	3,993	$0.00	39,744	No	4	A	Direct
Common Stock	Acquisiton	2017-02-08	2,382	$235.49	42,126	No	4	A	Direct
Common Stock	Acquisiton	2017-02-08	1,021	$164.84	43,147	No	4	A	Direct
Common Stock	Disposition	2017-02-08	6,145	$236.68	37,002	No	4	F	Direct
Common Stock	Disposition	2017-02-09	7,597	$239.57	29,405	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	A	Direct
No	4	A	Direct
No	4	F	Direct
No	4	S	Direct

Footnotes

Represents common shares acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated).
Includes 40.814 shares acquired under the Company's Employee Stock Purchase Plan from August 2, 2016 to February 6, 2017.
Represents common shares acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated), 50% of which vest immediately and the remaining 50% vest in two equal annual installments on February 8, 2018 and February 8, 2019.
Restricted stock units acquired through deferral of compensation under the Company's Management Stock Purchase Program.
Shares withheld to pay taxes upon vesting of performance-based restricted stock units granted under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated).
Sales are pursuant to a previously disclosed 10b5-1 plan.
Represents the weighted average sales price for price increments ranging from $239.47 to $239.83. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4.